Assessing the impact of glaucoma and its treatment on the person

 描述（由申请人提供）：青光眼是全球和美国视力损害和失明的主要原因之一。虽然青光眼通常是一种影响双眼的疾病，但在典型的眼科环境中，其对患者影响的临床评估是分别在每只眼睛上进行的。这掩盖了这样一个事实，即受青光眼影响的人双眼都有功能，用于控制青光眼的治疗可能会影响到人，而不仅仅是眼睛，即使这些治疗只对一只眼睛进行。这项研究的首要目标是评估青光眼对人而不是眼睛的影响。青光眼与抑郁症相关，因此我们打算评估新诊断的青光眼患者从诊断到治疗期间随访9年的抑郁症的患病率和预测因素。治疗青光眼的典型方法包括频繁施用（通常每天两次或三次）一种或多种局部药物（滴眼剂）以控制眼压。每种类型的药物都有一套独特的潜在症状与其使用相关。我们希望将报告的眼部和全身症状与特定药物以及添加第二种药物后的时间相关。治疗的目的是控制青光眼，并且通常测量的方式是通过每只眼睛的视野测试。由于青光眼患者使用双眼来发挥功能，因此我们希望探讨使用双眼评估时，视觉功能测量（如视野测试）之间的关系。 眼睛，使用用于联合收割机分别对每只眼睛进行视觉功能测量的方法，这是在临床上进行的典型测试，以代表双眼视觉功能。所有这些目标都依赖于从600多名参与者中收集的青光眼初始治疗临床试验的数据，即青光眼初始治疗合作研究。拟议的研究与国家眼科研究所的目标密切相关，以支持有关致盲性眼病，视觉障碍，视觉功能机制，视力保护以及部分视力或盲人的特殊健康问题和需求的应用临床研究。

 DESCRIPTION (provided by applicant): Glaucoma is one of the leading causes of visual impairment and blindness worldwide and in the United States. While glaucoma is usually a condition that affects both eyes, clinical assessments of its impact on patients in typical eye car settings are performed on each eye separately. This belies the fact that people affected by glaucoma function with both eyes, and treatments used to control glaucoma may impact on the person rather than only on the eye, even when those treatments are administered to only one eye. The overarching aim of the proposed research in this grant application is to assess the impact of glaucoma on the person rather than on the eye. Glaucoma has been associated with depression, and so we intend to evaluate depression in newly diagnosed glaucoma patients from the time of diagnosis through 9 years of follow-up during treatment, with respect to its prevalence and predictors. The typical approach to treating glaucoma involves frequent administration (often two or three times per day) of one or more topical medications (eye drops) to control eye pressure. Each type of medication has a unique set of potential symptoms associated with its use. We wish to relate reported ocular and systemic symptoms over time for a specific medication and after the addition of a second medication. The purpose of treatment is to control glaucoma, and the way that is typically measured is by means of a visual field test of each eye. Since a person with glaucoma uses both eyes to function, we wish to explore the relationship of visual function measures like the visual field test, when it is assessed using both eyes, with methods used to combine visual function measures taken on each eye separately, which is the typical test done in the clinic, to represent binocular visual function. All of these aims depend on data collected from over 600 participants in a clinical trial of initial treatments for glaucoma, the Collaborative Initial Glaucoma Treatment Study. The proposed research relates closely with the goals of the National Eye Institute, to support applied clinical research concerning the blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and needs of individuals who are partially-sighted or blind.